Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A. van den Bent MJ, et al. Among authors: idbaih a. Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13. Lancet Oncol. 2018. PMID: 30115593 Clinical Trial.
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K. Kaloshi G, et al. Among authors: idbaih a. Neurology. 2007 May 22;68(21):1831-6. doi: 10.1212/01.wnl.0000262034.26310.a2. Neurology. 2007. PMID: 17515545
Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.
Idbaih A, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, French P, Teepen JL, Delattre O, Delattre JY, van den Bent M, Hoang-Xuan K. Idbaih A, et al. Neuropathology. 2008 Aug;28(4):440-3. doi: 10.1111/j.1440-1789.2008.00863.x. Epub 2008 Feb 26. Neuropathology. 2008. PMID: 18312547
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M. van den Bent MJ, et al. Among authors: idbaih a. Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16. Clin Cancer Res. 2010. PMID: 20160062 Clinical Trial.
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, French P, Teepen J, Broët P, Delattre O, Mokhtari K, Sanson M, Delattre JY, van den Bent M, Hoang-Xuan K. Idbaih A, et al. J Neurooncol. 2011 Jun;103(2):221-30. doi: 10.1007/s11060-010-0380-9. Epub 2010 Sep 6. J Neurooncol. 2011. PMID: 20820870 Free PMC article. Clinical Trial.
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.
Ducray F, de Reyniès A, Chinot O, Idbaih A, Figarella-Branger D, Colin C, Karayan-Tapon L, Chneiweiss H, Wager M, Vallette F, Marie Y, Rickman D, Thomas E, Delattre JY, Honnorat J, Sanson M, Berger F. Ducray F, et al. Among authors: idbaih a. Mol Cancer. 2010 Sep 7;9:234. doi: 10.1186/1476-4598-9-234. Mol Cancer. 2010. PMID: 20822523 Free PMC article.
297 results